-
3 days ago | 
hcplive.com | Tim Smith
An announcement by Nektar Therapeutics has revealed significant findings from the 16-week induction phase of the company's ongoing phase 2b REZOLVE-AD trial have been yielded regarding the investigational agent rezpegaldesleukin for atopic dermatitis.1Rezpegaldesleukin, a selective interleukin (IL)-pathway agonist designed to expand regulatory T cells (Tregs), was shown to be effective at 16 weeks among patients with moderate-to-severe atopic dermatitis.
-
4 days ago | 
hcplive.com | Tim Smith
A wide array of physicians, researchers, and industry leaders gathered in Nashville, Tennessee, to attend the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference, a key meeting in the field of dermatology. Throughout the latest iteration of this yearly conference, late-breaking data that related specifically to atopic dermatitis.
-
5 days ago | 
hcplive.com | Tim Smith
Treatment of patients living with psoriasis with biologics, especially interleukin (IL)-17 inhibitors, notably raises their risk of superficial fungal infections, according to recent findings.1These data resulted from an analysis led by such investigators as Heli Liu, from the Department of Dermatology and Venereology at the Third Hospital of Shanxi Medical University in China.
-
1 week ago | 
hcplive.com | Tim Smith
The US Food and Drug Administration (FDA) has extended its period of review for ruxolitinib cream (OPZELURA) as a treatment for children ages 2 - 11 years with mild to moderate atopic dermatitis, despite the previous target action date having been set for June 2025.1The June 20 announcement by Incyte indicates that the new Prescription Drug User Fee Act (PDUFA) target action date has been pushed to September 19, 2025.
-
1 week ago | 
hcplive.com | Tim Smith
Older adults with atopic dermatitis aged ≥ 65 years who are treated with oral upadacitinib 15 mg as a once-daily monotherapy may attain optimal skin clearance and relief from itch, new findings suggest, along with notable quality of life and sleep improvements.1These findings were released as late-breaking data at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.
-
1 week ago | 
hcplive.com | Tim Smith
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of adult patients living with bullous pemphigoid.1 The June 20, 2025, approval announcement by Sanofi and Regeneron is based on positive clinical trial findings in the ADEPT trial and marks the first targeted therapy to receive approval from the FDA as well as the 8th indication for dupilumab in a disease with underlying type 2 inflammation.1 “Today’s approval extends the remarkable ability of...
-
1 week ago | 
hcplive.com | Tim Smith
A medium-dose inhaled corticosteroid along with a long-acting β2-agonist have been recommended in a new analysis for children with uncontrolled asthma on inhaled corticosteroid alone, and investigators urge against use of a leukotriene receptor antagonist alone.1These data resulted from a recent analysis conducted to assess the clinical efficacu of different pharmacological treatments among pediatric patients with uncontrolled asthma on inhaled corticosteroid.
-
1 week ago | 
hcplive.com | Tim Smith
Individuals with atopic dermatitis being treated with dupilumab are at an increased risk of developing psoriasis, new findings suggest, compared to individuals receiving other systemic drugs.1These data were the result of a recent analysis authored by a team of investigators, such as Teng-Li Lin, MD, from the department of dermatology at the Buddhist Tzu Chi Medical Foundation’s Dalin Tzu Chi Hospital in Taiwan.
-
1 week ago | 
hcplive.com | Tim Smith
Among males with androgenetic alopecia using dutasteride and those using finasteride, new findings suggest that both treatments have similar risks for sexual dysfunction.1These findings on dutasteride and finasteride, both classified as 5-alpha-reductase inhibitors (5ARIs), are the results of an analysis of the 2 treatments’ impacts on those with androgenetic alopecia related to sexual health and related adverse events (AEs).
-
2 weeks ago | 
hcplive.com | Tim Smith
Individuals with moderate-to-severe atopic dermatitis and a history of cigarette-smoking who were treated with upadacitinib for up to 6 years had comparable incidence rates of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and malignancy (excluding non-melanoma skin cancer) to those observed in a real-world population of people living with atopic dermatitis, new data suggest.1 These data were the result of a recent study presented at the 2025 Revolutionizing Atopic...
